Incorporating 13th HealthTech Investment Forum & 8th HealthTech Innovation Days
Caesarea, Israel
Nitinotes Ltd. is an early commercial-stage medical device company advancing endoluminal innovation for obesity care. Its flagship platform, EndoZip™, is the first fully automated, single-operator suturing system designed specifically for endoscopic sleeve gastroplasty (ESG).
Brainomix is a global pioneer in AI medical imaging, enabling precision medicine for better treatment decisions in stroke and lung fibrosis. Its flagship product, Brainomix 360 Stroke, is the world's first fully automated AI-imaging platform, designed for acute stroke assessment at all points of the patient pathway, facilitating more confident treatment and transfer decisions for patients in all hospitals, regardless of local resources or expertise. Brainomix 360 e-Lung is an FDA-cleared, AI-powered imaging software platform that automatically identifies and quantifies features on CT lung scans enabling clinicians to more easily identify changes over multiple scan timepoints. Founded as a spinout from the University of Oxford, Brainomix has offices in the UK, Ireland and the USA, and operations in more than 20 countries.
To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on LinkedIn.
München, Germany
hema.to is a Munich-based AI healthtech company building AI-supported software for automated flow cytometry analysis. Its cloud platform enables laboratories to go from raw data to standardized, reproducible results and reports within seconds. Designed to integrate seamlessly into all existing laboratory workflows, hema.to's product helps laboratories increase efficiency and scale case volumes without additional operational overhead.
Hamburg, Germany
iniuva. AI-powered orphan drug development.
iniuva is a Hamburg-based biotech. We develop Pharmacological Chaperones: small molecules that correct protein misfolding at its source, the underlying mechanism in roughly two thirds of patients with a genetic disease, some 34 million people in the EU and USA.
Our platform iniuvaVIU® answers that need: it predicts not just the structure of a misfolded protein but its function, so we design better drug candidates and move from discovery to IND in months rather than years. Because misfolding carries across many indications, the approach is not tied to a single therapeutic area.
Our B2B model fuels biopharma pipelines with de-risked, discovery-to-clinical-stage drug candidates for underserved markets.